PIN95 Resource use and Costs for Managing HCV Genotype 1 Patients in Colombia from the Payers Perspective  by Ariza, J.G. et al.
A680  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
had STD data and 1,985 had LTD data during year following diagnosis. Of these 
87% had at least one day of ABS, 21% at least one STD claim and 2% at least one 
LTD claim. Total ABS costs in the year following the HCV diagnosis were $17,439. 
Among those with claims, STD costs during year following diagnosis were $42,149 
and LTD costs were $50,422. A smaller subset of patients had productivity data 
available for the 2 year period following diagnosis (n= 215 [ABS], n= 748 [STD], n= 670 
[LTD]). Costs during year 2 were similar to first year cost- approximately $21,400 for 
ABS, $42,700 for STD and $55,500 for LTD. ConClusions: Novel treatments can be 
costly but potential reductions in productivity losses may offset these costs. Payers 
should consider broad and long-term impact of these medications when making 
reimbursement decisions.
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objeCtives: Patients treated with triple therapy regimens of a protease inhibi-
tor (PI), pegylated interferon and ribavirin, require monitoring to assess treatment 
response (HCV-RNA assays) and determine adverse event development (clinical 
review and laboratory tests). The aim of this study was to examine resource uti-
lisation associated with treatment of patients with HCV genotype-1 managed in 
an ambulatory hospital-based setting. Methods: Data on resource utilisation for 
patients prospectively enrolled in the Irish Hepatitis C Outcomes and Research 
network (ICORN) Treatment Registry, who reached end of treatment (EOT) were gath-
ered. Data on 1) attendances to outpatient clinics for clinical assessment, 2) labora-
tory tests (FBC, liver profile etc.) and 3) HCV-RNA assays were quantified. Results: 
A total of 50/241 patients have reached EOT to date. Telaprevir accounts for 36 
patients, of whom 30% fulfilled criteria for response guided therapy (RGT), while 29% 
of boceprevir-treated patients fulfilled criteria. A total of 1371 outpatient clinic visits 
were recorded for patients to EOT (mean 29.3 (range 10-51) (SD = 9)). There were 3481 
individual laboratory tests undertaken. A full blood count is the most commonly 
ordered investigation, n= 1179 (costs incurred € 18,864). A total of 382 HCV-RNA PCR 
assays were completed to EOT (mean of 7.10 (range 4-11 (SD = 2)) per patient. This 
was 250 in excess of expected numbers of HCV-RNA assays from SPC instruction. It 
was estimated that adherence to mandated HCV-RNA assays would result in cost 
savings of approximately € 9,000 or € 180 per patient treated. ConClusions: There 
is significant resource utilisation associated with the treatment of HCV patients in a 
hospital-based setting. Cost savings may be generated by the development of guid-
ance on laboratory monitoring, and careful adherence to decision rule time points. 
This may have implications for guideline development for monitoring of patients 
treated with new agents for HCV in the near future.
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objeCtives: To estimate the direct costs of HCV management for genotype 1 
patients throughout their lifetime based on the natural history of the disease from 
payer perspective in Colombia. Methods: Direct costs were estimated from a payer 
perspective by using a micro-costing approach of all relevant resources used to 
manage patients with HCV genotype 1 since the diagnosis for a lifetime perspective. 
Resources and clinical practice were identified, measured and valued for nine health 
states. Resource use and clinical patterns were validated with a panel of experts in 
managing HCV patients by applying a comprehensive survey. Each of the resources 
was valued based on standard national public lists of fees in Colombian pesos (when 
the list of fees was released? Is it up to date or not?). Total costs for each of the health 
states of the disease were calculated for a one year time horizon. Results: Direct 
cost were presented in US Dollars using the average year to date exchange rate (USD 
1 = COP 1,974). Estimated average direct cost for each health state per year: non 
diagnostic HCV (USD 512), chronic HCV F0-F3 (USD 1,440), compensated cirrhosis 
(USD 976), decompensated cirrhosis (USD 10,782), hepatocellular carcinoma (USD 
10,263), liver transplantation (USD 28,883), post-transplant (USD 1,933), monitoring 
drug therapy for HCV and the management of adverse events (USD 1,020), death 
(USD 15,538). ConClusions: Chronic HCV infection represents an important eco-
nomic and humanistic burden for health systems in the world. This micro-costing 
study provides valuable information for further economic cost of illness analysis 
from the Colombian payers setting. It also reflects severity and economic impact 
of HCV related health states.
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objeCtives: Studies on medical resource utilization (MRU) and related costs are 
important for evaluating the potential patient management and cost-effectiveness 
implications of antiviral treatments for Hepatitis C virus (HCV) infection. The objec-
tives of this study were (i) to compare the MRU and related costs for two treatment 
approaches, (ii) to identify the main drivers of resource use and costs, and (iii) to 
assess the effect of various treatment regimen attributes on MRU-related costs 
in a UK clinical setting. Methods: The analysis used data collected alongside 
the simeprevir (SMV) phase III trials for treatment-naïve genotype 1 HCV-infected 
patients; these data covered outpatient consultations with specialists, emergency 
The potential cost savings were summarised for a single patient and up-scaled for 
Switzerland. Results: They are estimated to add up to approximately 9 Mio CHF 
for Switzerland for all three scenarios. Scenario 2 contributed most with about 6.5 
Mio CHF (70%). For a single patient potential savings of about 10k CHF resulted for 
scenario 1 and 700k CHF for scenarios 2 and 3. The major share of potential savings 
accrues from adjusted antibiotic treatment and from avoidance of productivity 
losses. ConClusions: Even though these results are preliminary and partly based 
on assumptions, it is expected that the economic advantages are still attractive even 
when savings might be partly lower. Nevertheless, it is desirable to verify assump-
tions and potentials by clinical trials and pilot studies.
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objeCtives: Vaccination is the best way to prevent from life-threatening and 
debilitating infectious diseases that still lead to a huge epidemiological and eco-
nomic burden to societies. The French health authorities have recently decided 
to implement a “rendez-vous” in the vaccination calendar for individuals aged 65 
years old, to achieve optimal vaccination coverage rates and improve protection for 
elderly population against diphtheria, tetanus, seasonal influenza, pneumococcal 
diseases, pertussis and herpes zoster. The objective of this study was to assess from 
a governmental perspective the return on investment of the 65 year-old’ “rendez-
vous vaccinal” in France. Methods: A cohort model was developed to compare 
the mortality, morbidity, lifetime earnings and transfers of a cohort aged 65 with 
or without vaccination. The incremental total discounted lifetime direct and indi-
rect tax revenue gained, the reduction in direct medical and social insurance costs 
resulting from the vaccinations were estimated and compared to vaccination budg-
ets. Uncertainty was handled using univariate sensitivity analyses on vaccination 
coverage, epidemiological data, economic parameters and discount rates. Results: 
From the French government’s point of view, vaccinating individuals aged 65 years 
old age is estimated to produce favorable benefit cost-ratios [~1 up to 3]. The results 
suggest that every euro invested in vaccination is expected to at-least be paid back 
to the government due to increased tax revenues, social insurance and health care 
cost-savings. ConClusions: This macro-economic analysis approaches vaccina-
tion as an investment rather than a cost. From the French Government’s point of 
view, promoting actively vaccination for 65 year-old individuals in France will favor 
healthy ageing while producing positive returns on investment.
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objeCtives: While the life expectancy of timely antiretrovirally treated HIV 
infected adults converges to that of the general population, there are still imbal-
ances with regard to the labor market [Worthington et al. (2011); Dray-Spira et 
al. (2008); Rabkin et al. (2004); Goldman, Bao (2004)]. Previous studies of a French 
cohort find that unemployment of HIV patients is significantly related to health 
related factors such as the number of CD4 cells [Dray-Spira et al. (2007); Dray-
Spira et al. (2005)]. Based on data of a German cohort we aim to analyze drivers 
of unemployment of HIV infected individuals receiving antiretroviral therapy in 
specialized centers in Germany. Methods: We prospectively surveyed 656 HIV 
patients in the age of 18-60 over two years and collected data on potential factors 
that influence the propensity of unemployment (e. g. age, educational background, 
and disease related factors). By means of a logistic regression we identify signifi-
cant determinants of unemployment. Results: The unemployment rate within 
our sample is 29.9% which is much higher than the overall German unemployment 
rate of 6.6%. A poor level of education, concomitant mental diseases, and most of 
all advanced stage of HIV disease significantly determine the likelihood of being 
unemployed. Even controlling for other determinants of unemployment, moving 
from CDC stage A to CDC stage C increases the probability of unemployment 
by 180%. ConClusions: We confirm the results of earlier studies that health 
related factors among HIV patients significantly affects the probability of being 
unemployed. Specifically, the stage of HIV disease seems to be a good predictor of 
unemployment. From a health economic point of view, earlier start of antiretroviral 
treatment and deceleration of disease progression is not only beneficial for the 
patient but also for the economy as a whole.
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objeCtives: Payers, including employers, are struggling to balance cost of novel 
therapies with long-term benefits of the treatments. The goal of this analysis is 
to examine the potential benefit of treating patients with Hepatitis C virus (HCV) 
by evaluating indirect costs during the first year following diagnosis. Methods: 
Employed patients with HCV were identified using the Truven Health Analytics 
Health and Productivity Management Database from 2010-2012. Presence and 
number of days associated with absenteeism (ABS), short-term disability (STD) and 
long-term disability (LTD) were evaluated among patients with HCV and at least 12 
months of continuous enrollment for the year following diagnosis. Costs associated 
with reduced productivity were monetized using an average hourly wage (ABS) and 
a proportion of that wage (70% for STD/LTD) and are reported in US$. Results: A 
total of 3,250 patients met the study inclusion criteria (mean age: 51 years; 67% 
male). Availability of productivity data varied - 588 employees had ABS data, 2,175 
